Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients With Bipolar Depression With Acute Suicidality

First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol
byBill Haddad
January 3, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need
  • Company received Breakthrough Therapy Designation and a Special Protocol Assessment (“SPA”) for this trial helping to mitigate risks and accelerate the timing of this NRX-101 development program
  • First trial site has been contracted with others expected in near future, first dosing of patients is expected in early 2023
  • Company to meet with research analysts and investors in conjunction with the upcoming JP Morgan Healthcare Conference
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts